RAP 0.00% 20.5¢ raptor resources limited

Approval to Begin Adult Study

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
  1. 30,284 Posts.
    lightbulb Created with Sketch. 206
    ResApp Receives Approval to Begin Adult
    Study
    Perth, Western Australia, 14 December 2015 -- ResApp Health Limited (ASX:
    RAP), the developer of smartphone medical applications for the diagnosis and
    management of respiratory disease, is pleased to announce that it has received
    approval to enrol its first adult patient at the Joondalup Health Campus (JHC) in
    Perth, Western Australia. The Emergency Department (ED) at JHC provides
    emergency services to nearly 100,000 patients per year (80,000 adults and
    20,000 children), making it one of Australia’s busiest EDs. The study will gather
    data from adults presenting to the ED with respiratory conditions such as upper
    respiratory tract infections, bronchitis, pneumonia, asthma and chronic
    obstructive pulmonary disease. The aim of the study is to demonstrate that
    ResApp’s technology, shown to be highly accurate for diagnosis of childhood
    respiratory conditions, can be extended to adults.
    JHC Director of Medical Services, Dr Simon Wood said, “We are pleased to again
    work with The University of Queensland and ResApp to extend the very
    successful childhood study into adult patients. We look forward to seeing how
    digital health technologies can be integrated into the practice of medicine and
    improve patient care.”
    “We are excited to extend our clinical study to adults as an important next step
    for the company,” said Dr Tony Keating, CEO and Managing Director of ResApp.
    “With over 450 children enrolled in our paediatric study in just eight months, we
    have demonstrated the robustness of our machine learning algorithms to
    accurately diagnose the majority of childhood respiratory diseases. Including
    adults in the JHC study not only provides access to one of Australia’s busiest EDs,
    it utilises much of the same clinical team and logistics allowing us to achieve fast
    adult patient enrolment.”
    ResApp will again work with The University of Queensland to analyse the clinical
    data and is targeting enrolment of 400 patients with preliminary results
    expected in the first half of calendar 2016.
    ResApp plans to extend the adult study to a second site, one of the largest
    private emergency departments on the east coast of Australia. In-principle
    support has been given and the company plans to submit an application to that
    hospital’s Human Research Ethics Committee this month.
    - ENDS -
 
watchlist Created with Sketch. Add RAP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.